Sequencing of ctDNA was performed on blood samples through Guardant360 from the 243 patients with GIST (198 de-identified from the Guardant Health database and 45 from Sylvester Comprehensive Cancer ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer (TNBC), ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) ...

Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. This ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

This is the second highest number after thyroid cancer.Gastric cancer refers to a malignant tumor in the stomach, mainly ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.

The seriously ill brother of a Catholic man murdered by loyalists has pleaded with the British government to reveal the truth ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...